BTL-203

N/A

Report date: 2026/05/22 14:22:48

Base Information

Drug NameBTL-203

Drug Alias NameBTL-203

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionIgG receptor FcRn large subunit p51 inhibitors

TargetsIgG receptor FcRn large subunit p51

Therapy Area/IndicationsMyasthenia Gravis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBendao Biotechnology (Hangzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBendao Biotechnology (Hangzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsMyasthenia Gravis

Inactive IndicationsN/A

Other Information

ATC CodeN/A